# A Study for Assessing the Efficacy and Safety ParActin® in Individuals With Upper Respiratory Tract Infections

> **NCT06355661** · NA · UNKNOWN · sponsor: **Vedic Lifesciences Pvt. Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Upper Respiratory Tract Infections

## Interventions

- **DIETARY_SUPPLEMENT:** ParActin®: 300 mg + MCC: 100 mg (± 10%) per Capsule
- **DIETARY_SUPPLEMENT:** MCC: 400 mg (± 10%) per Capsule

## Key facts

- **NCT ID:** NCT06355661
- **Lead sponsor:** Vedic Lifesciences Pvt. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-05
- **Primary completion:** 2024-07-15
- **Final completion:** 2024-07-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06355661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06355661, "A Study for Assessing the Efficacy and Safety ParActin® in Individuals With Upper Respiratory Tract Infections". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT06355661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*